ReproCELL (4978) FY2026 Q3 Earnings Report

Quick View

Executive Summary

For the cumulative Q3 period, earnings deteriorated significantly due to the decline in revenue and the heavy fixed-cost burden, with losses widening in Operating Income, Ordinary Income, and Net Income. Revenue was ¥1.61B (¥2.07B in the previous year, YoY -22.2%), Operating Income was ¥-0.68B (¥-0.18B in the previous year), Ordinary Income was ¥-0.45B (¥-0.03B in the previous year), and Net Income was ¥-0.46B (¥-0.03B in the previous year). In addition to declining revenue in both the Research Support and Medical businesses, SG&A expenses (¥1.39B, 86.4% of revenue) substantially exceeded gross profit (¥0.71B), making the heavy fixed-cost structure relative to the scale of the business the primary cause of the earnings deterioration.

Factors Affecting Earnings

【Revenue】Revenue was ¥1.61B, representing a year-on-year decline of -22.2%. By segment, both businesses posted lower revenue: the core Research Support Business recorded ¥1.41B (YoY -19.0%), while the Medical Business recorded ¥0.20B (YoY -38.9%), with the Medical Business experiencing a particularly sharp decline. By region, revenue comprised ¥0.62B from the United States, ¥0.53B from the United Kingdom, ¥0.41B from Japan, and ¥0.05B from India, with overseas revenue accounting for approximately 71% of the total.

【Earnings】Although gross profit contracted to ¥0.71B (gross margin 44.4%) due to the decline in revenue, SG&A expenses remained high at ¥1.39B (86.4% of revenue), causing Operating Income to deteriorate to ¥-0.68B. On a segment basis, the Research Support Business generated ¥0.03B and the Medical Business recorded ¥-0.01B, securing combined profit of ¥0.02B; however, an adjustment of ¥-0.48B for company-wide expenses and other items substantially reduced consolidated earnings. Ordinary Income improved by ¥0.22B from the operating loss due to non-operating income of ¥0.25B (including foreign exchange gains of ¥0.09B and subsidy income of ¥0.10B), but these were non-operating factors, and Net Income remained at a loss of ¥-0.46B. This was a decline in both revenue and earnings.

Segment Analysis

The Research Support Business recorded Revenue of ¥1.41B (¥1.74B in the previous year, YoY -19.0%) and segment profit of ¥0.03B (¥0.39B in the previous year, YoY -91.3%), with profit shrinking at a substantially faster pace than revenue. The Medical Business recorded Revenue of ¥0.20B (¥0.33B in the previous year, YoY -38.9%), while segment earnings were ¥-0.01B, turning to a loss from the ¥0.09B profit recorded in the previous year. Against combined segment profit of ¥0.02B, the adjustment for company-wide expenses and other items was substantial at ¥-0.48B, resulting in a structure in which improved segment-level profitability alone cannot absorb the consolidated loss.

Key Financial Indicators

【Profitability】The Operating Margin was -42.0% and the Net Profit Margin was -28.5%, both significantly worse than in the same period of the previous year (equivalent Operating Margin of -8.7%). This reflects a structure in which SG&A expenses (86.4% of revenue) weigh heavily on the business amid declining revenue. Annualized ROE was -7.0%, indicating that shareholders’ equity is being impaired by the net loss. 【Cash Flow Quality】Non-operating income of ¥0.25B, one factor behind the improvement in Ordinary Income, included interest income of ¥0.06B, foreign exchange gains of ¥0.09B, and subsidy income of ¥0.10B, which have characteristics distinct from the Company’s core operating earning power. 【Investment Efficiency】Total asset turnover remains low, and the efficiency of revenue generation from invested assets is limited. R&D expenses were ¥0.47B, equivalent to 29.0% of revenue, indicating continued investment at a high level. 【Financial Soundness】The Equity Ratio was 84.4% and the Current Ratio was approximately 511%, both extremely high. Financial assets, comprising cash and deposits of ¥2.65B and securities of ¥4.20B, accounted for more than half of total assets, indicating limited concern regarding short-term funding.

Cash Flow Analysis

As figures from the statement of cash flows are not included in the disclosed data, cash trends are reviewed based on movements in the balance sheet. Cash and deposits were ¥2.65B, slightly down from ¥2.82B in the previous year, while current securities increased significantly to ¥4.20B, resulting in an increase in broadly defined liquidity comprising cash and securities. Current assets of ¥7.61B provided substantial coverage against current liabilities of ¥1.49B, and funding pressure from short-term liabilities was limited. No significant expansion was observed in working capital items such as accounts receivable, inventories, and accounts payable, and the financial base remained generally stable despite the net loss recorded for the period.

Earnings Quality

Ordinary Income improved from an Operating Loss of ¥-0.68B to ¥-0.45B, but the primary cause was non-operating income of ¥0.25B (interest income of ¥0.06B, foreign exchange gains of ¥0.09B, and subsidy income of ¥0.10B), all of which include temporary and non-recurring elements that do not reflect core operating earning power. Excluding these items, the underlying loss from the business can be interpreted as being larger. Comprehensive Income was ¥-0.20B, creating a divergence from the Net Loss of ¥-0.46B due to factors including valuation difference on securities of +¥0.21B; fluctuations in the market value of investment securities therefore contributed to the difference between earnings and comprehensive income. Overall, the improvement in earnings for the period was highly dependent on non-operating factors, and the quality of earnings was not necessarily high.

Earnings Forecast and Guidance

The full-year forecast is Revenue of ¥2.28B, Operating Income of ¥-0.84B, Ordinary Income of ¥-0.57B, and EPS of ¥-6.07. Cumulative progress rates are 70.7% for Revenue, 80.1% for Operating Income, and 79.3% for Ordinary Income. While revenue progress is slightly below the standard 75% level, progress against the loss items has reached around 80%, indicating deterioration at a pace somewhat ahead of plan in terms of earnings. Achieving the full-year forecast requires standalone Q4 Revenue of approximately ¥0.67B; given the progress to date, this presents a considerable hurdle. The earnings forecast was revised during the quarter.

Shareholder Returns

The Q2 dividend was ¥0, and the full-year dividend forecast is also ¥0, indicating a no-dividend policy. As the Company recorded a net loss for the period, the Payout Ratio cannot be calculated, confirming a stance that prioritizes conserving internal funds while operating at a loss. No information regarding share repurchases has been disclosed.

Risk Factors

1. Sharp deterioration in profitability: The Operating Margin was -42.0%, and SG&A expenses reached approximately 1.95 times gross profit, indicating that the current revenue scale cannot absorb fixed costs. Revenue declines are occurring simultaneously in both the Research Support Business (YoY -19.0%) and the Medical Business (YoY -38.9%).

2. High overseas revenue ratio and business composition risk: The United States and United Kingdom combined account for approximately 70% of consolidated revenue, resulting in high sensitivity to overseas research budget trends, foreign exchange fluctuations, and the regulatory environment. The Medical Business has turned from a profit in the previous year to a loss, increasing instability within the business portfolio.

3. Insufficient capacity to absorb company-wide expenses: Against combined segment profit of ¥0.02B, the adjustment for company-wide expenses and other items was substantial at ¥-0.48B, creating a structural issue in which improving the profitability of individual businesses alone cannot bring consolidated earnings into the black.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

While the industry median is generally in positive territory, the Company significantly underperforms in profitability.

Growth and Capital Efficiency

While revenue growth is typical among companies in the industry, the Company is experiencing a significant decline in revenue and also lags in growth.

※Source: Compiled by the Company

Key Points from the Financial Results

1. R&D expenses of ¥0.47B (29.0% of revenue) represent investment linked to future product and service revenue; however, they are currently progressing alongside declining revenue, and the investment has not yet converted into short-term earnings growth.

2. The improvement in Ordinary Income depends on non-operating factors such as foreign exchange gains and subsidy income rather than an improvement reflecting core operating earning power. This is an important consideration in evaluating earnings quality.

3. The Equity Ratio of 84.4% and Current Ratio of approximately 511% indicate a strong financial base and limited near-term concern regarding funding. However, if losses continue, cash consumption from R&D and SG&A expenses could gradually reduce financial flexibility.

Theoretical Share Price (Reference Value)

Sensitivity: ¥53–¥56 for ±1% in the cost of equity, and ¥53–¥55 for ±0.1 in ω.

Notes:

• As forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional as necessary.

---End of Report---